8-K - InMed Pharmaceuticals Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

InMed Pharmaceuticals Inc. announced positive preclinical data from human brain organoid neuroinflammation models supporting the INM-901 Alzheimer's disease program, showing dose-dependent reduction of pro-inflammatory markers IL-6 and IL-8. The results translate prior animal model findings to human-relevant systems, de-risking the program ahead of a planned pre-IND meeting in Q3/2026 and Phase 1 trial in 2027.

Key Takeaways

1INM-901 demonstrated significant reduction in neuroinflammation in LPS/IFN-γ-induced and Alzheimer's disease human 3D brain organoid models.

2Dose-dependent reduction of IL-6 and IL-8 pro-inflammatory markers observed.

3Consistent anti-inflammatory effects align with prior in vivo mouse Alzheimer's model and ex vivo LPS model data.

4Pre-IND meeting with FDA planned for Q3/2026; IND submission and Phase 1 trial targeted for 2027.

5Studies conducted in collaboration with Stem Pharm, Inc.

Current Report Details

Event Type

Regulation Fd

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act,

Regulation Fd

9.01

. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News rele

Exhibits Only

Source Document

Exhibits (2)

8-K

FORM 8-K

99.1

EXHIBIT 99.1